VTRS · 8-K · 20261008PR039024

Non-Opioid Pain Market Positioning

Viatris Inc · 2026-10-08 · Importance 52 · Surprise 42

Pacira generated approximately $746 million in total revenue in the twelve months ended June 30, 2026, and its commercial portfolio includes U.S. products EXPAREL for acute postsurgical pain and ZILRETTA for osteoarthritis knee pain. Viatris says it plans to use its global infrastructure to expand the products’ reach in selected international markets. Pacira reports that its therapies have helped nearly 20 million patients access non-opioid pain management. Viatris expects the products to complement its fast-acting meloxicam opportunity and expand its U.S. commercial, market-access and medical-affairs capabilities.

Key facts

• Viatris expects the Pacira transaction to be synergistic with its fast-acting meloxicam market opportunity. source
• Viatris expects the acquisition of EXPAREL and ZILRETTA to position it as a leader in non-opioid pain management therapies. source
• EXPAREL addresses acute postsurgical pain, and ZILRETTA addresses osteoarthritis knee pain. source